Elevated Tissue Expression of Thrombomodulatory Factors Correlates with Acute Symptomatic Carotid Plaque Phenotype

European Journal of Vascular and Endovascular Surgery

Volumn 38, Issue 1, 2009, Pages 20-25

  Sayed, S ^a,b   Cockerill, G W ^a,b   Torsney, E ^a,b   Poston, R ^c   Thompson, M M ^a,b   Loftus, I M ^a,b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Carotid plaque; Plaque instability; Thrombomodulation

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CHLORDANE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA; THROMBOCYTE FACTOR; THROMBOMODULATORY FACTOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; VASCULAR ENDOTHELIAL CADHERIN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CAROTID PLAQUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE COURSE; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; INCIDENCE; INTRAPLAQUE HEMORRHAGE; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SYMPTOM;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BLOOD COAGULATION FACTORS; CADHERINS; CAROTID ARTERIES; CAROTID ARTERY THROMBOSIS; DNA; ENDARTERECTOMY, CAROTID; ENDOTHELIUM, VASCULAR; FACTOR XA; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPOPROTEINS; MACROPHAGES; MALE; MIDDLE AGED; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 67349119431     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2009.02.020     Document Type: Article

References (17)

1. Rothwell P.M. Prediction and prevention of stroke in patients with symptomatic carotid stenosis: the high-risk period and the high risk patient. Eur J Vasc Endovasc Surg 35 (2008) 255-263
2. Loftus I.M., Naylor A.R., Bell P.R.F., and Thompson M.M. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 89 (2002) 680-694
3. Kragel A.H., Gertz S.D., and Roberts W.C. Morphologic comparison of frequency and types of acute lesions in the major epicardial coronary arteries in unstable angina pectoris, sudden coronary death and acute myocardial infarction. J Am Coll Cardiol 18 (1991) 801-808
4. Jander S., Sitzer M., Wendt A., Schroeter M., Buchkremer M., Siebler M., et al. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke 32 (2001) 850-854
5. Steins M.B., Padró T., Li C.X., Mesters R.M., Ostermann H., Hammel D., et al. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 145 (1999) 173-180
6. Falkenberg M., Tjärnström J., Ortenwall P., Olausson M., and Risberg B. Localization of fibrinolytic activators and inhibitors in normal and atherosclerotic vessels. Thromb Haemost 75 (1996) 933-938
7. Padró T., Steins M., Li C.X., Mesters R.M., Hammel D., Scheld H.H., et al. Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants. Cardiovasc Res 36 (1997) 28-36
8. Padró T., Emeis J.J., Steins M., Schmid K.W., and Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 15 (1995) 893-902
9. Luttun A., Lupu F., Storkebaum E., Hoylaerts M.F., Moons L., Crawley J., et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodelling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 22 (2002) 499-505
10. Redgrave J.N., Lovett J.K., Gallagher P.J., and Rothwell P.M. Histological assessment of 526 symptomatic carotid plaques in relation to the timing and nature of ischaemic symptoms: the Oxford plaque study. Circulation 114 (2006) e598
11. Penn M.S., and Topol E.J. Tissue factor, the emerging link between inflammation, thrombosis and vascular remodelling. Circ Res 89 (2001) 1-2
12. Crawley J.T., and Lane D.A. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 28 (2008) 233-242
13. Moreno P.R., Bernardi V.H., López-Cuéllar J., Murcia A.M., Palacios I.F., Gold H.K., et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 94 (1996) 3090-3097
14. Crawley J., Lupu F., Westmuckett A.D., Severs N.J., Kakkar V.V., and Lupu C. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 20 (2000) 1362-1373
15. Loftus I.M., Naylor A.R., Goodall S., Crowther M., Jones L., Bell P.R.F., et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 31 (2000) 40-47
16. Molloy K.J., Thompson M.M., Jones J.L., Schwalbe E.C., Bell P.R., Naylor A.R., et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 110 (2004) 337-343
17. Caplice N.M., Mueske C.S., Kleppe L.S., and Simari R.D. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 98 (1998) 1051-1057